Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.

A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Abstract Text:

    s yangS Yang,z s guoZ S Guo,m e o'malleyM E O'Malley,x yinX Yin,h j zehH J Zeh,d l bartlettD L Bartlett,

    To enhance further the safety and efficacy of oncolytic vaccinia virus, we have developed a new virus with targeted deletions of three viral genes encoding thymidine kinase and antiapoptotic/host range proteins SPI-1 and SPI-2 (vSPT). Infection of human and murine tumor cell lines yielded nearly equivalent or a log lower virus recovery in comparison to parental viruses. Viral infection activated multiple caspases in cancer cells but not in normal cells, suggesting infected cells may die via different pathways. In tumor-bearing mice, vSPT recovery from MC38 tumor was slightly reduced in comparison to two parental viruses. However, no virus was recovered from the brains and livers of mice injected with vSPT in contrast to control viruses. vSPT demonstrated significantly lower pathogenicity in nude mice. Systemic delivery of vSPT showed significant tumor inhibition in subcutaneous MC38 tumor, human ovarian A2780 and murine ovarian MOSEC carcinomatosis models; however, the tumor inhibition by vSPT was reduced compared with parental viruses. These results demonstrated that although deletion of these three viral genes further enhanced tumor selectivity, it also weakened the oncolytic potency. This study illustrates the complexity of creating a tumor-selective oncolytic virus by deleting multiple viral genes involved in multiple cellular pathways.

    A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Publishing Authors By Initials

    s yangS Yang,zs guoZS Guo,me o'malleyME O'Malley,x yinX Yin,hj zehHJ Zeh,dl bartlettDL Bartlett,

    For similar biological phenomena, cell phenomena, and immunity: biological phenomena: microbiologic phenomena: viral physiology: virus replication research abstracts see: biological phenomena, cell phenomena, and immunity: biological phenomena: microbiologic phenomena: viral physiology: virus replication research

    PUBMED ID PMID:

    MEDLINE DATE:

    A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Journal Published:

    PUBLICATION TYPE: Research Support, N.I.H., Extr

    Journal: Gene therapy

    VOLUME: 14

    Page Numbers: 638-47

    Journal Abbreviation: Gene Ther.

    ISSN: 0969-7128

    DAY: 1

    MONTH: 02

    YEAR: 2007

    A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9421525

    A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Keywords Mesh Terms:

    KEYWORDS: Virus Replication

    MESH TERMS: genetics

    Chemical & Substance for Abstract: A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Information

    Substance Name: Protein Kinases

    Registry Number: EC 2.7.1.37

    Grant and Affiliation Information for A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.

    AFFILIATION: University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY: United States NCI

    GRANT: CA100415

    ACRONYM: CA

    MEDLINETA: Gene Ther

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News